Kaposi Sarcoma - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Kaposi Sarcoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Kaposi Sarcoma - Pipeline Review, H1 2016', provides an overview of the Kaposi Sarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma
- The report reviews pipeline therapeutics for Kaposi Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Kaposi Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Kaposi Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Kaposi Sarcoma


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Kaposi Sarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kaposi Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Kaposi Sarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Kaposi Sarcoma - Overview 8
Pipeline Products for Kaposi Sarcoma - Comparative Analysis 9
Kaposi Sarcoma - Therapeutics under Development by Companies 10
Kaposi Sarcoma - Therapeutics under Investigation by Universities/Institutes 11
Kaposi Sarcoma - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Kaposi Sarcoma - Products under Development by Companies 15
Kaposi Sarcoma - Products under Investigation by Universities/Institutes 16
Kaposi Sarcoma - Companies Involved in Therapeutics Development 17
Aphios Corporation 17
AstraZeneca Plc 18
Biogenomics Limited 19
CytRx Corporation 20
Delenex Therapeutics AG 21
Tumorend, LLC 22
Vironika, LLC 23
Kaposi Sarcoma - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
aldoxorubicin hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
brolucizumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CM-101 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CSTATI-1 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
doxorubicin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
interferon alfa-2a - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
interferon alfa-2b - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
paclitaxel - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
selumetinib sulfate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule for Kaposi's Sarcoma - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
vif-1 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Kaposi Sarcoma - Recent Pipeline Updates 53
Kaposi Sarcoma - Dormant Projects 70
Kaposi Sarcoma - Discontinued Products 72
Kaposi Sarcoma - Product Development Milestones 73
Featured News & Press Releases 73
May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update 73
Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016 73
Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi's Sarcoma 74
Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages 75
Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 76
May 28, 2015: Delenex Presents Anti-Tumor Activity of DLX1008 78
Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients 78
Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma 79
Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi's Sarcoma 80
Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Number of Products under Development for Kaposi Sarcoma, H1 2016 8
Number of Products under Development for Kaposi Sarcoma - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Comparative Analysis by Unknown Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Kaposi Sarcoma - Pipeline by Aphios Corporation, H1 2016 17
Kaposi Sarcoma - Pipeline by AstraZeneca Plc, H1 2016 18
Kaposi Sarcoma - Pipeline by Biogenomics Limited, H1 2016 19
Kaposi Sarcoma - Pipeline by CytRx Corporation, H1 2016 20
Kaposi Sarcoma - Pipeline by Delenex Therapeutics AG, H1 2016 21
Kaposi Sarcoma - Pipeline by Tumorend, LLC, H1 2016 22
Kaposi Sarcoma - Pipeline by Vironika, LLC, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Kaposi Sarcoma Therapeutics - Recent Pipeline Updates, H1 2016 53
Kaposi Sarcoma - Dormant Projects, H1 2016 70
Kaposi Sarcoma - Dormant Projects (Contd..1), H1 2016 71
Kaposi Sarcoma - Discontinued Products, H1 2016 72